IMVT Quote, Financials, Valuation and Earnings

Electromed, Inc. has a net margin of -- compared to Immunovant, Inc.'s net margin of 12.65%. Immunovant, Inc.'s return on equity of -88.1% beat Electromed, Inc.'s return on equity of 18.89%.

Immunovant, Inc. has a consensus price target of $39.94, signalling upside risk potential of 49.41%. On the other hand Electromed, Inc. has an analysts' consensus of $36.00 which suggests that it could grow by 22.45%. Given that Immunovant, Inc. has higher upside potential than Electromed, Inc., analysts believe Immunovant, Inc. is more attractive than Electromed, Inc..

Immunovant, Inc. has a beta of 0.572, which suggesting that the stock is 42.758% less volatile than S&P 500. In comparison Electromed, Inc. has a beta of 0.266, suggesting its less volatile than the S&P 500 by 73.442%.

Immunovant, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Electromed, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Immunovant, Inc. pays -- of its earnings as a dividend. Electromed, Inc. pays out -- of its earnings as a dividend.

Immunovant, Inc. quarterly revenues are --, which are smaller than Electromed, Inc. quarterly revenues of $16.9M. Immunovant, Inc.'s net income of -$126.5M is lower than Electromed, Inc.'s net income of $2.1M. Notably, Immunovant, Inc.'s price-to-earnings ratio is -- while Electromed, Inc.'s PE ratio is 31.63x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Immunovant, Inc. is -- versus 3.92x for Electromed, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

InfuSystem Holdings, Inc. has a net margin of -- compared to Immunovant, Inc.'s net margin of 6.19%. Immunovant, Inc.'s return on equity of -88.1% beat InfuSystem Holdings, Inc.'s return on equity of 9.93%.

Immunovant, Inc. has a consensus price target of $39.94, signalling upside risk potential of 49.41%. On the other hand InfuSystem Holdings, Inc. has an analysts' consensus of $14.20 which suggests that it could grow by 59.37%. Given that InfuSystem Holdings, Inc. has higher upside potential than Immunovant, Inc., analysts believe InfuSystem Holdings, Inc. is more attractive than Immunovant, Inc..

Immunovant, Inc. has a beta of 0.572, which suggesting that the stock is 42.758% less volatile than S&P 500. In comparison InfuSystem Holdings, Inc. has a beta of 1.680, suggesting its more volatile than the S&P 500 by 68.01%.

Immunovant, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. InfuSystem Holdings, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Immunovant, Inc. pays -- of its earnings as a dividend. InfuSystem Holdings, Inc. pays out -- of its earnings as a dividend.

Immunovant, Inc. quarterly revenues are --, which are smaller than InfuSystem Holdings, Inc. quarterly revenues of $36.5M. Immunovant, Inc.'s net income of -$126.5M is lower than InfuSystem Holdings, Inc.'s net income of $2.3M. Notably, Immunovant, Inc.'s price-to-earnings ratio is -- while InfuSystem Holdings, Inc.'s PE ratio is 34.07x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Immunovant, Inc. is -- versus 1.34x for InfuSystem Holdings, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Revvity, Inc. has a net margin of -- compared to Immunovant, Inc.'s net margin of 6.76%. Immunovant, Inc.'s return on equity of -88.1% beat Revvity, Inc.'s return on equity of 3.05%.

Immunovant, Inc. has a consensus price target of $39.94, signalling upside risk potential of 49.41%. On the other hand Revvity, Inc. has an analysts' consensus of $114.63 which suggests that it could grow by 11.06%. Given that Immunovant, Inc. has higher upside potential than Revvity, Inc., analysts believe Immunovant, Inc. is more attractive than Revvity, Inc..

Immunovant, Inc. has a beta of 0.572, which suggesting that the stock is 42.758% less volatile than S&P 500. In comparison Revvity, Inc. has a beta of 1.054, suggesting its more volatile than the S&P 500 by 5.36%.

Immunovant, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Revvity, Inc. offers a yield of 0.27% to investors and pays a quarterly dividend of $0.07 per share. Immunovant, Inc. pays -- of its earnings as a dividend. Revvity, Inc. pays out 11.63% of its earnings as a dividend. Revvity, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Immunovant, Inc. quarterly revenues are --, which are smaller than Revvity, Inc. quarterly revenues of $698.9M. Immunovant, Inc.'s net income of -$126.5M is lower than Revvity, Inc.'s net income of $47.2M. Notably, Immunovant, Inc.'s price-to-earnings ratio is -- while Revvity, Inc.'s PE ratio is 51.51x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Immunovant, Inc. is -- versus 4.35x for Revvity, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Viridian Therapeutics, Inc. has a net margin of -- compared to Immunovant, Inc.'s net margin of -49.03%. Immunovant, Inc.'s return on equity of -88.1% beat Viridian Therapeutics, Inc.'s return on equity of -47.79%.

Immunovant, Inc. has a consensus price target of $39.94, signalling upside risk potential of 49.41%. On the other hand Viridian Therapeutics, Inc. has an analysts' consensus of $41.76 which suggests that it could grow by 34.94%. Given that Immunovant, Inc. has higher upside potential than Viridian Therapeutics, Inc., analysts believe Immunovant, Inc. is more attractive than Viridian Therapeutics, Inc..

Immunovant, Inc. has a beta of 0.572, which suggesting that the stock is 42.758% less volatile than S&P 500. In comparison Viridian Therapeutics, Inc. has a beta of 0.945, suggesting its less volatile than the S&P 500 by 5.488%.

Immunovant, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Viridian Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Immunovant, Inc. pays -- of its earnings as a dividend. Viridian Therapeutics, Inc. pays out -- of its earnings as a dividend.

Immunovant, Inc. quarterly revenues are --, which are smaller than Viridian Therapeutics, Inc. quarterly revenues of $70.6M. Immunovant, Inc.'s net income of -$126.5M is lower than Viridian Therapeutics, Inc.'s net income of -$34.6M. Notably, Immunovant, Inc.'s price-to-earnings ratio is -- while Viridian Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Immunovant, Inc. is -- versus 35.06x for Viridian Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.